Medivation Inc. (MDVN) and ASTELLAS PHARMA INC.’s (ALPMY) jointly developed drug, Xtandi, is likely to make a dent in the sales of Johnson & Johnson’s (JNJ) drug Zytiga given its more favorable safety profile in treating pre-chemotherapy prostate cancer patients.
By The Burrill Report:
By Vinay Singh
Johnson & Johnson (JNJ) released interim data from a late-stage study that showed its prostate cancer drug, Zytiga, improved survival of men with less advanced forms of the disease. The newly released data may help expand the indication of the already approved drug to treat a larger patient pool.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced that its drug Avastin had been approved by the US Food and Drug Administration (FDA) for treating women suffering from ovarian cancer, which is resistant to platinum-containing chemotherapy.
European health regulators had previously approved the drug as a treatment for advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer, and ovarian cancer.
By John Eastman:As Prostate cancer cases continue to be diagnosed in the U.S. in abundance (estimated 238,590 new cases of prostate cancer will be diagnosed with nearly 30,000 deaths) drug makers are also intensifying their effort to confront this late stage of life disease in men. The average age at the time of diagnostics is 67.
The EU Committee for Medicinal Products for Human Use recently recommended Roche Holding Ltd.’s (RHHBY) experimental therapy drug Avastin – which, used in combination with chemotherapy, is a treatment for women with platinum-resistant ovarian cancer – for approval by the European Commission. The drug has already been approved for use as a first-stage treatment option for patients suffering from late-stage ovarian cancer.
By Peter Geschek:
In its first full year on the market, in 2012, Johnson & Johnson's prostate cancer medicine Zytiga generated $961 million in revenues which make it a "near blockbuster". (A drug is considered blockbuster above $1 billion in sales).Zytiga is the most successful oral oncology drug launch in history. It is now approved in 65 countries and helped a huge number of men everywhere.
Bristol-Myers Squibb Co (BMY) has reported another triumph for nivolumab, its high profile PD-1 cancer drug. Topline late-stage trial results for the drug were presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid today. The study demonstrated a higher response rate in advanced melanoma patients treated with the drug, compared to the control arm which was treated with chemotherapy. All patients in the study had been previously treated with the company’s cancer drug Yervoy.